SCHEMBL6897980

SCHEMBL6897980

CCCCNC(=O)CN1CCNCCN(CC(=O)N(CCCC)CC(=O)NCCCC)CC1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 8/20 0.63
CHRM5 P08912 2/20 0.40
CHRM3 P20309 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 3/20 0.35
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
KDM4E B2RXH2 2/20 0.34
QRFPR Q96P65 1/20 0.34
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1900359 0.83 SIGMAR1 (0.67) SIGMAR1CHRM5CHRM3SMN1; SMN2MEN1
SCHEMBL8395095 0.82 SIGMAR1 (0.65) SIGMAR1CHRM5CHRM3SMN1; SMN2MEN1
SCHEMBL10687011 0.79 SIGMAR1 (0.65) SIGMAR1CHRM5CHRM3SMN1; SMN2ALDH1A1
SCHEMBL7862964 0.77 SIGMAR1 (0.61) SIGMAR1CHRM5CHRM3ALDH1A1GNAI3
SCHEMBL7376521 0.77 SIGMAR1 (0.85) SIGMAR1CHRM5CHRM3GNAI3GNAO1
SCHEMBL6897984 0.76 ALDH1A1 (0.57) SIGMAR1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL1905216 0.75 SIGMAR1 (0.71) SIGMAR1CHRM5CHRM3SMN1; SMN2MEN1
SCHEMBL2945928 0.74 SIGMAR1 (0.81) SIGMAR1CHRM5CHRM3GNAI3GNAO1
SCHEMBL11697620 0.72 SIGMAR1 (0.88) SIGMAR1CHRM5CHRM3POLBALDH1A1
SCHEMBL28391170 0.71 SIGMAR1 (0.64) SIGMAR1CHRM5CHRM3SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5874573-A Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy CONCAT, INC. (US) 1999-02-23 US claimed
EP-1382332-A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent Chelator LLC (US) 2004-01-21 EP disclosed
US-6469162-B1 SUCH COMPOUNDS INHIBIT MAMMALIAN, BACTERIAL, AND FUNGAL CELL REPLICATION AND ARE USEFUL IN THE TREATMENT OF NEOPLASIA, INFECTION, INFLAMMATION, IMMUNE REPONSE, AND IN TERMINATION OF PREGNANCY CONCAT, LTD. 2002-10-22 US disclosed
US-6165996-A Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis CONCAT, INC. (US) 2000-12-26 US disclosed
EP-0955044-A2 Method of inhibiting bacterial or fungal growth using a complexing agent CONCAT LTD. (US) 1999-11-10 EP disclosed
EP-0841951-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT LTD. (US) 1998-05-20 EP disclosed
WO-1997001360-A9 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS 1997-07-17 WO disclosed
WO-1997001360-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT, LTD. (US) 1997-01-16 WO disclosed